James R Berenson, MD
Oncotherapeutics · James R. Berenson MD, Inc. · James R. Berenson, M.D., Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James R Berenson, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:24 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04519476 · Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.Oncotherapeutics · unknown · Refractory Multiple Myeloma · principal investigator
- Ph1NCT03110822 · A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsOncotherapeutics · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT03104270 · Combination Study for High Risk Multiple Myeloma PatientsOncotherapeutics · terminated · Multiple Myeloma · principal investigator
- Ph2NCT02294357 · Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibOncotherapeutics · terminated · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT02206425 · Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsOncotherapeutics · completed · Multiple Myeloma · principal investigator
- Ph2NCT02188368 · Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma PatientsOncotherapeutics · terminated · Multiple Myeloma · principal investigator
- Ph2NCT01695330 · Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensOncotherapeutics · terminated · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT01541332 · Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaOncotherapeutics · unknown · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT01365559 · Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing TreatmentsOncotherapeutics · completed · Multiple Myeloma · principal investigator
- Ph2NCT01160484 · Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple MyelomaOncotherapeutics · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT00743288 · Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaOncotherapeutics · completed · Multiple Myeloma · principal investigator
- Ph2NCT00742404 · Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaOncotherapeutics · unknown · Multiple Myeloma and Plasma Cell Neoplasm · principal investigator
- Ph2NCT00317811 · Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaOncotherapeutics · completed · Multiple Myeloma and Plasma Cell Neoplasm · principal investigator
- Ph1NCT00316940 · Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaOncotherapeutics · completed · Multiple Myeloma and Plasma Cell Neoplasm · principal investigator
- Ph2NCT00085345 · Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaOncotherapeutics · withdrawn · Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 19 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.